Antiangiogennaya terapiya v lechenii glioblastomy: obzor i sobstvennye klinicheskie dannye


Cite item

Full Text

Abstract

References

  1. Кобяков Г.Л. Химиотерапия в комплексном лечении больных с первичными злокачественными опухолями головного мозга. Автореф. дис. … д-ра мед. наук. М., 2011.
  2. Смолин А.В., Кобяков Г.Л., Конев А.В. и др. Возможности антиангиогенной терапии при рецидивах глиом высокой степени злокачественности. Фарматека (Онкология). 2009; 18: 41-8.
  3. Кобяков Г.Л., Смолин А.В. Новые стратегии в лечении злокачественных глиом: краткий обзор научных публикаций ежегодного съезда общества нейроонкологии (SNO 2010) в Монреале. Фарматека (Онкология). 2011; 7: 41-9.
  4. Maher EA, McKee AC. Neoplasms of the central nervous system. In Atlas of diagnostic oncology. 3th ed. Ed.: A.Skarin, G.Canellos. London: Elsevier Science 2003; 5-10.
  5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
  6. Central Brain Tumor Registry of the United States (CBTRUS). 2010 CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. http://www.cbtrus.org/reports/reports.html
  7. National Comprehensive Cancer Network clinical practice guidelines in oncology-central nervous system cancers 2010; 1. http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf
  8. Stupp R, Mason WP, van den Bent MJ et al. European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10): 987-96.
  9. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17 (8): 2572-8.
  10. Prados MD, Lamborn K, Yung WK et al. North American Brain Tumor Consortium: a phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 2006; 8 (2): 189-93.
  11. Cloughesy TF, Filka E, Kuhn J et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003; 97 (9 Suppl.): 2381-6.
  12. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83 (5): 588-93.
  13. Inai T, Mancuso M, Hashizume H et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165 (1): 35-52.
  14. Huang J, Frischer JS, Serur A et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003; 100 (13): 7785-90.
  15. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 2007; 7 (11): 1537-60.
  16. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008, 7 (12): 1152-60.
  17. Salmaggi A, Eoli M, Frigerio S et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003; 62 (3): 297-303.
  18. Takano S, Yoshii Y, Kondo S et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996; 56 (9): 2185-90.
  19. Nam DH, Park K, Suh YL, Kim JH. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 2004; 11 (7): 863-9.
  20. Dickson PV, Hamner JB, Sims TL et al. Bevacizumab induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13 (13): 3942-50.
  21. Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66 (16): 7843-8.
  22. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23): 2335-42.
  23. Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 2005; 7 (3). Abstr. 369.
  24. Friedman HS, Prados M, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27 (28): 4733-40.
  25. Desjardins A, Herndon JE, Dowell JM et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13 (4): 1253-9.
  26. Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25 (30): 4722-9.
  27. Desjardins A, Vredenburgh JJ, Reardon DA et al. Long-term survival from the initial trial of bevacizumab and irinotecan. Abstr. J Clin Oncol 2010; 28 (15 Suppl.): 191s.
  28. Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009; 75 (1): 156-63.
  29. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007; 67 (2): 323-6.
  30. Levin VA, Bidaut L, Hou P et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2010.
  31. Torcuator R, Zuniga R, Mohan YS et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009; 94 (1): 63-8.
  32. Cloughesy T, Vredenburgh JJ, Day B et al. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN stud. Abstr. J Clin Oncol 2010; 28 (15 Suppl.): 181s.
  33. Semrad TJ, O'Donnell R, Wun T et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106 (4): 601-8.
  34. Puduvalli VK, Giglio P, Groves MD et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 2008; 10 (2): 216-22.
  35. Gruber Fadul CE, Kingman LS, Meyer LP et al. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol 2008; 90 (2): 229-35.
  36. Groves MD, Puduvalli VK, Chang SM et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007; 81 (3): 271-7.
  37. Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18 (4): 708-15.
  38. Vredenburgh JJ, Yang JC, Haworth L et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349 (5): 427-34.
  39. Narayana A, Kelly P, Golfinos J et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009; 110 (1): 173-80.
  40. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurol 2008; 70 (10): 779-87.
  41. Verhoeff JJ, Lavini C, van Linde ME et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 2010; 21 (8): 1723-7.
  42. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7 (9): 987-9.
  43. Fine HA, Wen PY, Maher EA et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003; 21 (12): 2299-304.
  44. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25 (33): 5165-71.
  45. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27 (5): 740-5.
  46. Reardon DA, Fink KL, Mikkelsen T et al. Randomized phase II study of cilengitide, an integrin-targeting arginineglycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26 (34): 5610-7.
  47. Fink K, Mikkelsen T, Nabors LB et al. Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study. Abstr. J Clin Oncol 2010; 28 (15 Suppl.): 182s.
  48. De Groot JF, Wen PY, Lamborn K et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomideresistant glioblastoma: NABTC 0601. Abstr. J Clin Oncol 2008; 26 (15 Suppl.): 94s.
  49. Wen PY, Prados M, Schiff D et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). Abstr. J Clin Oncol 2010; 28 (15 Suppl.): 181s.
  50. Narayana A, Golfinos JG, Fischer I et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 2008; 72 (2): 383-9.
  51. Lai A, Filka E, McGibbon B et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008; 71 (5): 1372-80.
  52. Lai A, Nghiemphu P, Green RM et al. Updated results of phase II trial of bevacizumab in combination with temozolomide andregional radiation therapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme. Abstr. Neuro Oncol 2009; 11 (5): 632.
  53. Gruber ML, Kunnakkat S, Medabalmi P et al. Change in pattern of relapse in newly diagnosed high-grade glioma following bevacizumab therapy. Abstr. J Clin Oncol 2010; 28 (15 Suppl.): 184s.
  54. Nicholas MK, Lucas RV, Arzbaecher J et al. Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme. Preliminary results of a phase II study. Abstr. J Clin Oncol 2009; 27 (15 Suppl.): 91s.
  55. Vredenburgh JJ, Desjardins A, Reardon DA et al. Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). Abstr. J Clin Oncol 2010; 28 (15 Suppl.): 185s.
  56. Hofland KF, Poulsen HS, Sørensen MP et al. First-line therapy with bevacizumab and irinotecan vs bevacizumab and temozolomide and delayed concomitant radiotherapy in newly diagnosed primary glioblastoma multiforme: early results from a randomized phase II study. Abstr. Neuro Oncol 2009; 11 (5): 620.
  57. van Linde ME, Verhoeff JJ, Stalpers LJ et al. Feasibility of combined treatment with bevacizumab, radiotherapy, and temozolomide in resectable and unresectable newly diagnosed glioblastoma multiforme. Abstr. Neuro Oncol 2009; 11 (5): 628.
  58. Chinot O, de La Motte T, Zeaiter A et al. Preclinical and clinical rationale for a phase III trial of bevacizumab combined with the current standard of care in patients with newly diagnosed glioblastoma multiforme (ND-GBM). Abstr. Neuro Oncol 2009; 11 (5): 628.
  59. Omuro AM, Beal K, Karimi S et al. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). Abstr. J Clin Oncol 2010; 28 (15 Suppl.): 188s.
  60. Stupp R, Hegi ME, Neyns B et al. Phase I-IIa trial of cilengitide and temozolomide with concomitant radiotherapy, followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28 (16): 2712-8.
  61. Brandes AA, Stupp R, Hau P et al. EORTC study 26041-22041: phase I-II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 2010; 46 (2): 348-54.
  62. Drappatz J, Norden AD, Wong ET et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2010; 78 (1): 85-90.
  63. Nabors LB, Fiveash JB, Markert JM et al. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 2010; 67 (3): 313-9.
  64. Niyazi M, Ganswindt U, Schwarz SB et al. Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 2010.
  65. Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29: 142-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 69203 от 24.03.2017 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 63964 от 18.12.2015 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies